000			03282cam a2200349 a 4500
003			EG-GiCUC
005			20250223032806.0
008			210828s2021 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.09.M.Sc.2021.Ma.E
100	0		_aMarina Ramsis Fouad Youssef
245	1	0	_aEffect of vildagliptin in treatment of experimentally induced {u2013}ulcerative colitis in rats / _cMarina Ramsis Fouad Youssef ; Supervised Hala Ahmed Fahmy Zaki , Ayman Elsayed Mohamed Elsahar , Rania Mohamed Kamel Hassan Mohamed Salama
246	1	5	_aدراسة تأثير ال{u٠٦ء٤}لداجلبتن فى نموذج تجريبى لالتهاب القولون التقرحى فى الجرذان
260			_aCairo : _bMarina Ramsis Fouad Youssef , _c2021
300			_a136 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
520			_aUlcerative colitis (UC) is a chronic bowel disease depicted by the involvement of pro-inflammatory cytokines.The release of these cytokines is regulated by phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/nuclear factor-kappa B (NFmB) and cAMP response element-binding protein (CREB) signaling pathways as well as over expression of microRNA 146a (miR-146a) and long non-coding RNA interferon gamma antisense 1 (lncRNA IFNG-AS1). Vildagliptin (Vilda), a dipeptidyl peptidase IV (DPP-IV) inhibitor, has an anti-inflammatory, antioxidant and anti-apoptotic effects which were established in various models. However, its possible protective effect in UC has not been clarified. Hence, the current study aimed to explore the possible prophylactic effect of different doses of Vilda against acetic acid (AA)-induced UC in rats. Forty-eight adult male Wistar rats were divided into six groups: control, Vilda (10 mg/kg/day; p.o.), AA, AA+Vilda (5 mg/kg/day; p.o.), AA+Vilda (10 mg/kg/day; p.o.) and AA+sulfasalazine (Sulfa) (100 mg/kg/day; p.o.).Low- and high-dose Vilda showed a significant improvement in the disease activity index (DAI) and macroscopic assessment markers. Vilda has markedly modulated the expression of lncRNA IFNG-AS1 and miR-146a, as well as PI3K/Akt/NFmB, CREB and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathways, which was reflected in alleviated oxidative stress, inflammation and apoptosis. Such outcomes were more prominent with the high-dose Vilda against low-dose Vilda and Sulfa. Moreover, the histological examination showed almost intact histological features in Vilda-treated groups when compared to AA group. In conclusion, Vilda can be regarded as a new promising therapeutic alternative against UC with higher benefit shown with high-dose Vilda
530			_aIssued also as CD
653		4	_aPI3K/Akt/CREB
653		4	_aUlcerative colitis
653		4	_aVildagliptin
700	0		_aAyman Elsayed Mohamed Elsahar , _eSupervisor
700	0		_aHala Ahmed Fahmy Zaki , _eSupervisor
700	0		_aRania Mohamed Kamel Hassan Mohamed Salama , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c81841 _d81841